Outlook Therapeutics
OTLK
70 hedge funds and large institutions have $32.6M invested in Outlook Therapeutics in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 21 reducing their positions, and 7 closing their positions.
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
11% more funds holding
Funds holding: 63 → 70 (+7)
0% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 21
0.08% less ownership
Funds ownership: 0.61% → 0.53% (-0.08%)
29% less capital invested
Capital invested by funds: $45.9M → $32.6M (-$13.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.19M |
| 2 |
Renaissance Technologies
New York
|
+$1.62M |
| 3 |
Two Sigma Advisers
New York
|
+$1.04M |
| 4 |
Two Sigma Investments
New York
|
+$889K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$375K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$814K |
| 2 |
Morgan Stanley
New York
|
-$347K |
| 3 |
Axa
Paris,
France
|
-$315K |
| 4 |
LNC
Lincoln National Corp
Radnor,
Pennsylvania
|
-$268K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$144K |
OTLK Hedge Fund Activity: Q4 2021 in Review
70 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q4 2021, worth a combined $32.6M — down 29% from $45.9M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new OTLK positions and 7 closed out — a net gain of 7 holders — while 21 added to existing stakes and 21 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.19M. The largest seller was Millennium Management, cutting an estimated $814K.
- 70 institutional investors held Outlook Therapeutics (OTLK) as of Q4 2021, up from 63 in Q3 2021.
- Funds reported $32.6M of Outlook Therapeutics stock for Q4 2021, down 29% quarter-over-quarter.
- 14 funds opened new Outlook Therapeutics positions in Q4 2021 and 7 closed out, a net change of +7 holders.
- The largest Outlook Therapeutics buyer in Q4 2021 was Vanguard Group, an estimated $2.19M added.
- The largest Outlook Therapeutics seller in Q4 2021 was Millennium Management, an estimated $814K sold.
Based on aggregated 13F filings for Q4 2021.